Yuekang Pharmaceutical announced that its wholly-owned subsidiaries Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd. have recently obtained approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” agreeing to inject YKYY031 for advanced solid tumors. Injectable YKYY031 is a general-purpose mRNA tumor vaccine intended for the treatment of advanced solid tumors.

Zhitongcaijing · 2d ago
Yuekang Pharmaceutical announced that its wholly-owned subsidiaries Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd. have recently obtained approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” agreeing to inject YKYY031 for advanced solid tumors. Injectable YKYY031 is a general-purpose mRNA tumor vaccine intended for the treatment of advanced solid tumors.